NCT01359163View on ClinicalTrials.gov

A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Therapeutic Equivalency
Interventions
DRUG

etynodiol diacetate

tablet, 0.5 mg, single dose

DRUG

etynodiol diacetate

tablet, 0.5 mg, single dose

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01359163 - A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects | Biotech Hunter | Biotech Hunter